[1] Tomasoni D, Adamo M, Lombardi CM, Metra M. Highlights in heart failure. ESC Heart Fail 2019; 6: 1105−1127. doi: 10.1002/ehf2.12555 [2]

Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation 2019; 139: e56−e28.

[3]

Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation 2018; 137: e67−492.

[4] Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123: 933−944. doi: 10.1161/CIR.0b013e31820a55f5 [5] Chen J, Dharmarajan K, Wang Y, Krumholz HM. National trends in heart failure hospital stay rates, 2001 to 2009. J Am Coll Cardiol 2013; 61: 1078−1088. doi: 10.1016/j.jacc.2012.11.057 [6] Mozaffarian D, Benjamin EJ, Go AS, et al. Executive summary: heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 2016; 133: 447−454. doi: 10.1161/CIR.0000000000000366 [7] Dharmarajan K, Rich MW. Epidemiology, pathophysiology, and prognosis of heart failure in older adults. Heart Fail Clin 2017; 13: 417−426. doi: 10.1016/j.hfc.2017.02.001 [8] Yokokawa T, Yoshihisa A, Kanno Y, et al. Clinical features of extremely elderly patients with heart failure. Geriatr Gerontol Int 2017; 17: 2194−2199. doi: 10.1111/ggi.13060 [9] Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol 2016; 13: 368−378. doi: 10.1038/nrcardio.2016.25 [10] Konstam MA. Home monitoring should be the central element in an effective program of heart failure disease management. Circulation 2012; 125: 820−827. doi: 10.1161/CIRCULATIONAHA.111.031161 [11] Lee WC, Serag H, Ohsfeldt RL, et al. Racial disparities in type of heart failure and hospitalization. J Immigr Minor Health 2019; 21: 98−104. doi: 10.1007/s10903-018-0727-4 [12] McCallum W, Tighiouart H, Kiernan MS, et al. Relation of kidney function decline and NT-proBNP with risk of mortality and readmission in acute decompensated heart failure. Am J Med 2020; 133: 115−122. doi: 10.1016/j.amjmed.2019.05.047 [13] Miles JA, Quispe R, Mehlman Y, et al. Racial differences and mortality risk in patients with heart failure and hyponatremia. Plos One 2019; 14: e0218504. doi: 10.1371/journal.pone.0218504 [14] Screever EM, Meijers WC, van Veldhuisen DJ, et al. New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations. Expert Opin Pharmacother 2017; 18: 645−655. doi: 10.1080/14656566.2017.1316377 [15] Buddeke J, Valstar GB, Van Dis I, et al. Mortality after hospital admission for heart failure: improvement over time, equally strong in women as in men. BMC Public Health 2020; 20: 36. doi: 10.1186/s12889-019-7934-3 [16] Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail 2020; 22: 1342−1356. doi: 10.1002/ejhf.1858 [17]

Pollard K, Scommegna P. The health and life expectancy of older Blacks and Hispanics in the United States. Population Reference Bureau 2013; 28: 1−8.

[18]

Geruso M. Black-white disparities in life expectancy: how much can the standard SES variables explain? Demography 2012; 49: 553−574.

[19]

Yao L, Robert SA. Examining the racial crossover in mortality between African American and white older adults: a multilevel survival analysis of race, individual socioeconomic status, and neighborhood socioeconomic context. J Aging Res 2011; 2011: 132073.

[20] Lynch SM, Brown JS, Harmsen KG. Black-white differences in mortality compression and deceleration and the mortality crossover reconsidered. Res Aging 2003; 25: 456−483. doi: 10.1177/0164027503254675 [21] Corti MC, Guralnik JM, Ferrucci L, et al. Evidence for a black-white crossover in all-cause and coronary heart disease mortality in an older population: the North Carolina EPESE. Am J Public Health 1999; 89: 308−314. doi: 10.2105/AJPH.89.3.308 [22] Jao GT, Chiong JR. Hyponatremia in acute decompensated heart failure: mechanisms, prognosis, and treatment options. Clin Cardiol 2010; 33: 666−671. doi: 10.1002/clc.20822 [23] Gheorghiade M, Rossi JS, Cotts W, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med 2007; 167: 1998−2005. doi: 10.1001/archinte.167.18.1998 [24] Rossi J, Bayram M, Udelson JE, et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care 2007; 9: 82−86. doi: 10.1080/17482940701210179 [25] Elgendy IY, Hill JA, Szady AD, et al. Systolic blood pressure, heart rate, and outcomes in patients with coronary disease and heart failure. ESC Heart Fail 2020; 7: 124−130. doi: 10.1002/ehf2.12534 [26] Böhm M, Robertson M, Borer J, et al. Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial. J Am Heart Assoc 2016; 5: e002160. doi: 10.1161/JAHA.115.002160 [27] Ambrosy AP, Vaduganathan M, Mentz RJ, et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. Am Heart J 2013; 165: 216−225. doi: 10.1016/j.ahj.2012.11.004 [28] Gheorghiade M, Vaduganathan M, Ambrosy A, et al. Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Fail Rev 2013; 18: 107−122. doi: 10.1007/s10741-012-9315-1 [29] Zhang Y, Wang C, Zhang J, et al. Low systolic blood pressure for predicting all-cause mortality in patients hospitalised with heart failure: a systematic review and meta-analysis. Eur J Prev Cardiol 2019; 26: 439−443. doi: 10.1177/2047487318784092 [30] Wikstrand J, Wedel H, Castagno D, McMurray JJ. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. J Intern Med 2014; 275: 134−143. doi: 10.1111/joim.12141 [31] Lee TT, Chen J, Cohen DJ, Tsao L. The association between blood pressure and mortality in patients with heart failure. Am Heart J 2006; 151: 76−83. doi: 10.1016/j.ahj.2005.03.009